Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer

被引:134
|
作者
Viney, RC
Boyer, MJ
King, MT
Kenny, PM
Pollicino, CA
McLean, JM
McCaughan, BC
Fulham, MJ
机构
[1] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Med Oncol Unit, Sydney Canc Ctr, Sydney, NSW 2007, Australia
[2] Royal Prince Alfred Hosp, Cardiothorac Surg Unit, PET Unit, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept PET & Nucl Med, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia
关键词
D O I
10.1200/JCO.2004.04.126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Positron emission tomography (PET) is a costly new technology with potential to improve preoperative evaluation for patients with non-small-cell lung cancer (NSCLC). There is increasing pressure for PET to be included in standard diagnostic work-up before decisions about surgical management of NSCLC. The resource implications of its widespread use in staging NSCLC are significant. Methods A randomized controlled trial was conducted to investigate the impact of PET on clinical management and surgical outcomes for patients with stage I-II NSCLC. The primary hypothesis was that PET would reduce the proportion of patients with stage I-II NSCLC who underwent thoracotomy by at least 10% through identification of patients with inoperable disease. Results One hundred eighty-four patients with stage I-II NSCLC were recruited and randomly assigned; 92% had stage I disease. Following exclusion of one ineligible patient, 92 patients were assigned to no PET and 91 to PET. Compared with conventional staging, PET upstaged 22 patients, confirmed staging in 61 and staged two patients as benign. Stage IV disease was rarely detected (two patients). PET led to further investigation or a change in clinical management in 13% of patients and provided information that could have affected management in a further 13% of patients. There was no significant difference between the trial arms in the number of thoracotomies avoided (P = .2). Conclusion For patients who are carefully and appropriately staged as having stage I-II disease, PET provides potential for more appropriate stage-specific therapy but may not lead to a significant reduction in the number of thoracotomies avoided. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:2357 / 2362
页数:6
相关论文
共 50 条
  • [11] Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients With Non-Small-Cell Lung Cancer
    Skoura, Evangelia
    Datseris, Ioannis E.
    Platis, Ioannis
    Oikonomopoulos, Georgios
    Syrigos, Konstantinos N.
    CLINICAL LUNG CANCER, 2012, 13 (03) : 181 - 187
  • [12] Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography
    Lardinois, D
    Weder, W
    Hany, TF
    Kamel, EM
    Korom, S
    Seifert, B
    von Schulthess, GK
    Steinert, HC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (25): : 2500 - 2507
  • [13] Role of positron emission tomography computed tomography (PET-CT) in stage I non-small cell lung cancer (NSCLC)
    Lee, Sang Hoon
    Ryu, Woo Kyung
    Yong, Seung Hyun
    Oh, Goeun
    Kim, Eun Young
    RESPIROLOGY, 2023, 28 : 315 - 315
  • [14] Positron Emission Tomography/Computed Tomography Thoracic Nodal Staging of Non-Small-Cell Lung Cancer
    Cheung, W. S. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2023, 26 (01): : 4 - 5
  • [15] Prognostic value of positron emission tomography in resected stage I non-small cell lung cancer
    Goodgame, Boone W.
    Dehdashti, Farrokh
    Yang, Zhiyun
    Shriki, Jabi
    Gao, Feng
    Patterson, Alexander
    Zolle, Jennifer
    Meyers, Bryan
    Siegel, Barry
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S314 - S314
  • [16] Invasive aspergillosis mimicking stage 111A non-small-cell lung cancer on FDG positron emission tomography
    Wilkinson, MD
    Fulham, MJ
    Mccaughan, BC
    Constable, CJ
    CLINICAL NUCLEAR MEDICINE, 2003, 28 (03) : 234 - 235
  • [17] Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
    Pieterman, RM
    van Putten, JWG
    Meuzelaar, JJ
    Mooyaart, EL
    Vaalburg, W
    Koëter, GH
    Fidler, V
    Pruim, J
    Groen, HJM
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04): : 254 - 261
  • [18] How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer?
    Liewald, F
    Grosse, S
    Storck, M
    Guhlmann, A
    Halter, G
    Reske, S
    Sunder-Plassmann, L
    THORACIC AND CARDIOVASCULAR SURGEON, 2000, 48 (02): : 93 - 96
  • [19] Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer
    Thomas, DM
    Mitchell, PLR
    Berlangieri, SU
    Tochon-Danguy, H
    Knight, S
    Clarke, CP
    Scott, AM
    MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (04) : 227 - 227
  • [20] Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer
    O'Donnell, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (05) : 236 - 237